INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of GSK plc – GSK

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving GSK plc and its officers or directors, following a negative FDA advisory vote impacting the company's stock price [1][3]. Group 1: Investigation Details - Pomerantz LLP is representing investors of GSK plc and is looking into claims of securities fraud or other unlawful business practices [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the investigation [1]. Group 2: Stock Price Impact - On July 17, 2025, GSK announced that the FDA Oncologic Drugs Advisory Committee voted against the benefit/risk profile of Blenrep at the proposed dosage, leading to a decline in GSK's ADR price by $1.81, or 4.73%, closing at $36.47 [3].